When GLP-1 drugs first entered the market, many expected a sharp decline in indulgence categories like chocolate.
“The top reason to eat chocolate is to satisfy a craving. And if GLP-1s do quell ‘food noise’ and therefore cravings, that could pose a threat.”
– Kiti Soininen, category director for UK food and drink research at market research firm Mintel
However, the reality unfolded differently. Lindt recently reported that its premium chocolate sales rose by 17% among GLP-1 users, whereas the increase was only 6.5% among non-GLP-1 users.
GLP-1 users are increasingly trading high-calorie chocolates for functional, high-quality alternatives. Barry Callebaut reports that 87% of consumers now desire healthy ingredients in chocolate confectionery due to GLP-1 drug adoption. However, a gap remains as quite a few commercial products currently target satiety or GLP-1 support specifically.
Texture-forward, satiety-promoting, permissible indulgent chocolates that align with the evolving needs of GLP-1 users is a huge market opportunity. Consumers want creamy, crunchy, joyful treats that support their weight management goals, not derail them. Also, many users discontinue medication due to side effects, making appetite-suppressing formats not just helpful, but a competitive advantage.
Brands like Nestlé and ADM were among the first to market GLP-1-friendly products last year, entering through supplements, beverages, snacks, and gummies. Now, chocolate is emerging as the next evolving category in the GLP-1 space.
Our analysis revealed that many companies in China are already on the move. Pharma leaders like Huahai Pharmaceutical and Liaoning Bazi International Trade are using inulin, MCTs, whey protein, collagen peptides, and microencapsulation techniques to align chocolates with this emerging trend.
Huahai Pharmaceutical’s appetite-suppressing chocolate uses inulin, MCTs, and whey protein
The patented chocolate has a high fat content (70–80% total mass). It includes functional ingredients such as inulin, medium-chain triglycerides (MCT), and whey protein, which help enhance satiety and reduce abdominal fat.
It has a loose honeycomb microstructure for a fluffy texture, non-sticky silky feel, and melt-in-the-mouth properties.
The method regulates moisture levels, stabilizes cocoa butter crystal structure, and uses a two-stage freezing and drying process. This helps produce appetite-suppressing chocolate that withstands heat and retains its shape even at 80°C.
Adding liquid MCT or linseed oil directly to the formulation can cause fat bloom in chocolates. To address this, formulators are overcoming this challenge by converting them into microcapsule powders.
Recommended Read
This ketogenic chocolate formulation microencapsulates MCTs and linseed oil diglycerides to avoid fat bloom
Liaoning Bazi International Trade holds a patent for a ketogenic weight-loss chocolate that uses microencapsulated functional oils.
The chocolate formulation contains MCT, linseed oil diglyceride, conjugated linoleic acid glyceride, whey protein, psyllium husk, and collagen peptides.
Additionally, arabinose, phospholipids, and polyglycerol ricinoleate are added to stabilize cocoa butter crystals during two-stage emulsification. Together, these steps help maintain appearance, texture, and flavor stability.
Apart from that, food scientists are also exploring micro-encapsulated bitter secoiridoids (Gentiana lutea), digestive-resistant peptides, and lactoferrin to formulate GLP-1 boosting chocolate confections. But this research is scattered across patents and research papers. Formulators have to run fragmented searches to find the ideal ingredient.
Our AI research tool can connect all the relevant research papers, patents, and product information docs in a single interface to boost the productivity of formulators. They can simply ask, “Which ingredients and techniques are being used to develop appetite-suppressing GLP-1 chocolates?” and start discovering today!
Find solutions to constraint-based R&D challenges
Suzhou Sphinx Food’s chocolate includes lipid-lowering polypeptides to reduce fat accumulation in consumers
Cocoa butter contains nearly 60% saturated fat. It contributes to chocolate’s rich taste and smooth texture. Reducing it often compromises the mouthfeel and overall sensory quality of the chocolate.
However, with marketing bans on foods high in fat, sugar, or salt, such as HFSS in the UK, food companies must innovate to minimize the ill effects of ingredients like cocoa butter on consumers.
Suzhou Sphinx Food Co Ltd has made a novel chocolate formulation designed to address the high-fat content issue by incorporating a lipid-lowering polypeptide. This innovation uses 2 to 5 parts by weight of the polypeptide, which is blended with standard raw materials like cocoa butter, cocoa powder, sucrose powder, and skimmed milk powder.
These polypeptides help reduce cholesterol deposition and fat accumulation in the consumer’s body, while maintaining chocolate’s taste and texture.
Which other ingredients are being researched for GLP-1-friendly foods?
Most foods that claim satiety still rely on broad levers like protein enrichment, fiber loading, or glycemic control. But the commercial landscape is shifting. Formulators are now moving toward targeted GLP-1 stimulation with novel bioactive peptides, prebiotic fibers, and fermentation-derived compounds. However, many of these ingredients introduce bitterness, formulation instability, and labeling complexity in the end product. Therefore, only a fraction is making it to scalable, consumer-ready formats.
We have curated a breakdown of commercialized ingredients, validated formulations, and real product examples already being used by leading brands in GLP-1-friendly foods. Fill out the form below to access the report.
